Application Serial No.: 10/540,296 Filing Date: January 20, 2006 Docket: 976-28 PCT/US

Response to Final Office Action issued June 20, 2008

Page 2 of 7

## AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

1-25: (Canceled)

- 26. (Currently Amended) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition emprising consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, wherein the pharmaceutical composition is administered rectally.
- (Previously Presented) The method according to claim 26, wherein the pharmaceutical
  composition comprises recombinant streptokinase and a pharmacologically acceptable
  diluent carrier or excipient.
- (Previously Presented) The method according to claim 27, wherein the recombinant streptokinase has a concentration of 50,000 to 1,500,000 IU per gram of the pharmaceutical composition.
- (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises ethylenediaminetetraacetic acid (EDTA).
- (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium diclofenae.
- (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium salicylate.

Application Serial No.: 10/540,296 Filing Date: January 20, 2006 Docket: 976-28 PCT/US Response to Final Office Action issued June 20, 2008 Page 3 of 7

- 32. (Cancelled)
- (Currently Amended) The method according to claim 32 26, wherein the pharmaceutical composition is a suppository.